Two patient deaths halt trial of Juno’s new approach to treating cancer

(By Damian Garde and Meghana Keshavan for STAT)

In a major blow to a new approach to treating cancer, two patients taking an experimental therapy from Juno Therapeutics have died following severe brain swelling, the company said Wednesday. It’s the second time Juno’s experimental therapy1 has been tied to fatal side effects. Continue reading article here…

stat-logo

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.